Search results

• New Findings in Chronic Pain Described from University of California San Francisco (UCSF) (Usability and acceptability of virtual reality for chronic pain management among diverse patients in a safety-net setting: a qualitative analysis)

  Lee, C. L. Y.

  7/31/23

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Research Conducted at University of British Columbia Has Updated Our Knowledge about Drug Research [Safety of Fecal Microbiota, Live-jslm (Rebyota((Tm))) In Individuals With Recurrent Clostridioides Difficile Infection: Data From Five ...]

  Lee, C. L. Y.

  7/13/23

  1 item of Media coverage

  Medicine

  Press/Media: Research

• What happens to a child when parents go to prison?

  Lee, C. L. Y.

  11/26/22

  1 item of Media coverage

  Medicine

  Press/Media: Research

• A child without a home; What happens to a child when parents go to prison

  Lee, C. L. Y.

  11/26/22

  1 item of Media coverage

  Medicine

  Press/Media: Research

• What happens to a child when parents go to prison

  Lee, C. L. Y.

  11/25/22

  3 items of Media coverage

  Medicine

  Press/Media: Research

• What happens to a child when parents go to prison

  Lee, C. L. Y.

  11/25/22

  2 items of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix Release Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo

  Lee, C. L. Y.

  6/7/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix Release Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo

  Lee, C. L. Y.

  5/30/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix Release Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo

  Lee, C. L. Y.

  5/28/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

  Lee, C. L. Y.

  5/27/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix Release Landmark Phase 3 Data on Efficacy of Investigational RBX2660 Versus Placebo

  Lee, C. L. Y.

  5/27/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivot...

  Lee, C. L. Y.

  5/24/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

  Lee, C. L. Y.

  5/23/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring und Rebiotix stellen bahnbrechende Phase-3-Daten vor, welche die überlegene Wirksamkeit des Prüfpräparats RBX2660 bei verringerten Rezidiven von C. difficile-Infektionen gegenüber Placebo belegen

  Lee, C. L. Y.

  5/22/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

  Lee, C. L. Y.

  5/22/21

  4 items of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

  Lee, C. L. Y.

  5/21/21

  17 items of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection

  Lee, C. L. Y.

  5/21/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021

  Lee, C. L. Y.

  5/13/21 → 5/18/21

  11 items of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week(R) (DDW) 2021

  Lee, C. L. Y.

  5/14/21

  4 items of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021

  Lee, C. L. Y.

  5/14/21

  2 items of Media coverage

  Medicine

  Press/Media: Research

• Ferring und Rebiotix präsentieren wegweisende Ergebnisse zum in der Erprobung befindlichen, mikrobiombasierten Lebend-Biotherapeutikum RBX2660 auf der Digestive Disease Week® (DDW) 2021

  Lee, C. L. Y.

  5/13/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week (DDW) 2021

  Lee, C. L. Y.

  5/13/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021

  Lee, C. L. Y.

  5/13/21

  17 items of Media coverage

  Medicine

  Press/Media: Research

• The Effect of a Personalized Oral Health Education Program on Periodontal Health in an At-Risk Population: A Randomized Controlled Trial

  Lee, C. L. Y.

  1/1/21

  1 item of Media coverage

  Medicine

  Press/Media: Research

• Ucsf Dermatology Fellowship

  Lee, C. L. Y. & Clark, D. A.

  10/8/19

  1 item of Media coverage

  Medicine

  Press/Media: Research